Physician profile
William E Davis
NPI 1891753216
$37,417.07
in general payments reported to CMS, 2019-2025
16 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2021: $2,288 · 2022: $6,817 · 2023: $5,392 · 2024: $4,512 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Consulting Fee: $8,058 · Travel and Lodging: $2,607 · Food and Beverage: $2,234 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,250.00 |
| Consulting Fee | $8,057.75 |
| Travel and Lodging | $2,607.31 |
| Food and Beverage | $2,233.67 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17,914.37 | 2023-2025 | Uplizna, Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $7,869.99 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $4,127.38 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $3,024.21 | 2022 | |
| Astrazeneca Uk Limited | $1,305.95 | 2024 | Saphnelo |
| Ani Pharmaceuticals, INC. | $1,275.00 | 2022 | |
| Glaxosmithkline, LLC. | $624.82 | 2021-2025 | Benlysta |
| Abbvie INC. | $513.54 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $247.08 | 2022-2024 | Acthar |
| Ucb, INC. | $167.85 | 2022-2025 | Bimzelx |
| Pfizer INC. | $142.36 | 2019-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $129.53 | 2024 | Arcalyst |
| Sobi, INC | $35.21 | 2024 | |
| Horizon Therapeutics Plc | $20.76 | 2021 | |
| Esperion Therapeutics, INC. | $19.02 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.